Comparison 6. Efficacy ‐ febuxostat 80 mg/day versus allopurinol 200 or 300 mg/day.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of gout flares	3	2325	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.98, 1.27]
1.1 8 weeks	1	530	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.91, 1.64]
1.2 24 weeks	1	1333	Risk Ratio (M‐H, Fixed, 95% CI)	1.47 [0.92, 2.37]
1.3 52 weeks	1	462	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.88, 1.15]
2 Serum uric acid <6.0 mg/dL at final visit	3	2193	Risk Ratio (M‐H, Random, 95% CI)	1.80 [1.55, 2.09]
2.1 24‐28 weeks	2	1702	Risk Ratio (M‐H, Random, 95% CI)	1.69 [1.49, 1.93]
2.2 52 weeks	1	491	Risk Ratio (M‐H, Random, 95% CI)	2.04 [1.70, 2.45]
3 Change in serum uric acid concentration from baseline at final visit	2	1041	Mean Difference (IV, Random, 95% CI)	‐1.24 [‐1.50, ‐0.99]
3.1 8 weeks	1	535	Mean Difference (IV, Random, 95% CI)	‐1.38 [‐1.59, ‐1.16]
3.2 52 weeks	1	506	Mean Difference (IV, Random, 95% CI)	‐1.12 [‐1.30, ‐0.94]